Evidence map›Paper›PMID 29770299›Full record

ReviewTranslational pediatrics2018

Regenerative medicine therapy for single ventricle congenital heart disease.

Chetan Ambastha, Gregory J Bittle, David Morales, Nathaniel Parchment, Progyaparamita Saha, Rachana Mishra, Sudhish Sharma, Alexander Vasilenko, Muthukumar Gunasekaran, Manal T Al-Suqi and 3 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Current state of the art in hypoplastic left heart syndrome.Frontiers in cardiovascular medicine · 2022
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Chetan AmbasthaDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Gregory J BittleDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
David MoralesDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Nathaniel ParchmentDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Progyaparamita SahaDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Rachana MishraDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Sudhish SharmaDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Alexander VasilenkoDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Muthukumar GunasekaranDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Manal T Al-SuqiDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Deqiang LiDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Peixin YangDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
Sunjay KaushalDivision of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
University of Maryland, Baltimore · US

Funding

Interdisciplinary Training Program Muscle BiologyT32AR007592 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI Aikaterini Kontrogianni-Konstantopoulos · 1996 to 2026
$11.7M
Mechanism of transplanted neonatal cardiac progenitor cells to repair ischemic myocardiumR01HL118491 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SCHUMACKER, PAUL T · 2014 to 2024
$4.4M
The Role of C-Kit Positive Cardiac Progenitors in Maternal Diabetes-Induced Heart Defects and the Therapeutic Values of These CellsR01HL139060 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI KAUSHAL, SUNJAY, YANG, PEIXIN · 2017 to 2020
$2.4M
NHLBI NIH HHS R01 HL118491NHLBI NIH HHS R01 HL139060NIAMS NIH HHS T32 AR007592
6 · The paper itself

Abstract

One of the most complex forms of congenital heart disease (CHD) involving single ventricle physiology is hypoplastic left heart syndrome (HLHS), characterized by underdevelopment of the left ventricle (LV), mitral and aortic valves, and narrowing of the ascending aorta. The underdeveloped LV is incapable of providing long-term systemic flow, and if left untreated, the condition is fatal. Current treatment for this condition consists of three consecutive staged palliative operations: the first is conducted within the first few weeks of birth, the second between 4 to 6 months, and the third and final surgery within the first 4 years. At the conclusion of the third surgery, systemic perfusion is provided by the right ventricle (RV), and deoxygenated blood flows passively to the pulmonary vasculature. Despite these palliative interventions, the RV, which is ill suited to provide long-term systemic perfusion, is prone to eventual failure. In the absence of satisfying curative treatments, stem cell therapy may represent one innovative approach to the management of RV dysfunction in HLHS patients. Several stem cell populations from different tissues (cardiac and non-cardiac), different age groups (adult-

Indexed as

congenitalHeart defectsheart failurehypoplastic left heart syndrome (HLHS)regenerative medicinestem cells

Identifiers

PMID29770299
PMCPMC5938254
OpenAlexW2802812956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.